Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review

Józwiak M, Bauer M, Kamysz W, Kleczkowska P · Pharmaceuticals

Catalogues the pleiotropic preclinical effects and the growing patent estate, notes few reported adverse effects, and raises theoretical concerns that sustained angiogenesis and raised NO and eNOS could carry tumour and neurodegenerative risk; concludes no regulator has approved it because comprehensive human studies do not exist.

Population

Literature and patent review of BPC 157 biology, safety and commercial activity

Intervention

n/a

Comparator

n/a

Limitations

The tumour and neurodegeneration concerns are mechanistic speculation, not observed findings; the review's statement on WADA status is out of step with the current Prohibited List, on which BPC-157 remains prohibited at all times under S0.